The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- DSP to Solely Develop Therapeutic Cancer Vaccines, Terminating Joint Development Agreement with Chugai
April 10, 2013
- Teva Japan: Pres. Shimada to Retire, Eli Lilly’s Kikushige to Take Helm
April 9, 2013
- Kowa, Daiichi Sankyo to End Livalo, Olmetec Marketing Partnership in June
April 9, 2013
- Eisai Sets Up Sales Subsidiary in Russia
April 9, 2013
- Ajinomoto Acquires US-Based Althea Technologies to Expand Biotech Operations
April 9, 2013
- Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
- Astellas Collaborates with Ambrx for Discovery and Development of Novel ADCs for Oncology Fields
April 9, 2013
- Novo Nordisk’s FY2012 Sales Dip 0.8% with Insulin Market Subdued by DPP-4 Inhibitors
April 8, 2013
- Abbott Japan Sales Decline 3.2% in 2012 Due to Product Transfer to AbbVie
April 8, 2013
- Survey by JCSOA Finds Big Increase in Use of CMRs to Detail Long-Listed and Non-Priority Products
April 8, 2013
- Teijin Acquires 10% Stake in Kyorin for Strategic Alliance
April 8, 2013
- Bell Medical Solutions Concludes Business Alliance Agreement for CRO Business with inVentiv Health Clinical
April 8, 2013
- Allegra Generic Versions Expected to Be Further Promoted: Pharmacist Survey
April 5, 2013
- Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
- MPD Begins Marketing BindRen in Germany and Austria
April 5, 2013
- Daiichi Sankyo Ends ATK Inhibitor Agreement with ArQule
April 5, 2013
- AnGes to Acquire Exclusive Rights for CIN Therapeutic Vaccine for Cervical Precancerous Lesions in Major Countries
April 5, 2013
- MTPC Agrees to Transfer Tanabe Europe Shares to API in Tokyo
April 4, 2013
- Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
- Mochida Aims at Sales of 104 Billion Yen in FY2015
April 4, 2013
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…